Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2008 Biotech Stock Picking for Charity -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (112)	1/14/2008 10:16:21 AM
From: idos	Read Replies (1) \| Respond to of 322

The US Supreme Court's ‘KSR' ruling on obviousness has persuaded the country's Court of Appeals to reverse a district court decision that Lupin had infringed a patent protecting King's Altace (ramipril) ACE-inhibitor brand until 29 October 2008. Three appeals judges found that all the asserted claims of US patent 5,061,722 were obvious in light of prior art. It ain't over till the fat lady sings - King said it would file a motion for a rehearing. But Xopenex and BTW Lunesta too are both enantiomers of previously known compounds and it will be easier for the generic com to attack their patent.